Today: 21 May 2026
American Express stock price slips after Q4 results: dividend hike, spending and rate-cap risk in focus
31 January 2026
2 mins read

American Express stock price slips after Q4 results: dividend hike, spending and rate-cap risk in focus

New York, January 30, 2026, 19:23 (EST) — Trading continues after hours.

  • American Express shares fell 1.8% by Friday’s close, with after-hours trading hovering close to that level.
  • The card issuer forecasted 2026 EPS between $17.30 and $17.90, with revenue expected to rise 9% to 10%.
  • Investors are balancing the expense of updating premium cards with steady travel and dining spending.

American Express Company shares ended Friday down 1.8% at $352.17 and showed little movement in after-hours trading. The decline followed the release of the company’s fourth-quarter results and its 2026 targets.

The numbers matter because the card business has become a real-time gauge of consumer resilience, particularly among wealthier customers. American Express relies heavily on affluent users, so its spending trends often appear stronger than the wider retail landscape.

Behind the scenes, costs are mounting. The company’s premium-card overhaul has driven up rewards and marketing expenses, with returns that don’t always show up right away.

For the quarter ending Dec. 31, revenue net of interest expense climbed 10% to $18.98 billion. Diluted earnings came in at $3.53 per share. Billed business, a stand-in for card spending, increased 9% to $445.1 billion. Expenses rose 10% to $14.5 billion. Provisions for credit losses—funds set aside for bad loans—jumped to $1.4 billion, as the net write-off rate edged up to 2.1%. Stephen J. Squeri said the company anticipates 2026 revenue growth between 9% and 10%, with earnings per share expected at $17.30 to $17.90. The quarterly dividend is set to rise roughly 16%, reaching $0.95.

Christophe Le Caillec noted that spending on the company’s cards by Gen Z and millennials has surpassed that of Gen X in the U.S. consumer segment. “We’re not projecting any discontinuity,” he added, highlighting steady demand in travel, dining, and luxury sectors. Meanwhile, Truist Financial analysts pointed out that the cost of the Platinum card refresh is hitting this quarter, ahead of a clearer rise in new accounts. Reuters

Cardholder spending jumped to $506.2 billion this quarter, up from $464 billion a year ago, while outstanding card loans increased to $213 billion from $199.1 billion, the company disclosed to the Associated Press. The U.S. Platinum refresh raised the annual fee to $895 and introduced perks like a $400 dining credit. AmEx also noted that younger customers are making up a larger share of the spending mix.

The selloff extended beyond AmEx. Visa’s shares dropped on Friday as well, with both stocks ranking among the largest drags on the Dow Jones Industrial Average that day.

Policy risks loom over the entire group. Donald Trump has proposed a one-year cap limiting credit-card interest rates to 10%, which would need congressional approval. On the earnings call, Squeri dismissed the 10% cap as “not the answer.” Analysts at William Blair noted AmEx’s premium clientele might soften the blow compared to the broader industry but highlighted significant uncertainty about how such a rule would be enforced. American Banker

U.S. cash markets remain closed until Monday, Feb. 2, leaving traders to watch for follow-through. The key question: will broker notes emphasize the rising expense run-rate or highlight steady spending? Credit trends will also stay in focus as loan balances continue to climb.

American Express will report first-quarter results on April 24. Investors will watch to see if the costly premium-card revamp is driving new sign-ups and if credit losses remain under control.

Stock Market Today

  • Teradyne, Kulicke and Soffa, Impinj, Microchip, IPG Photonics Stocks Slide on U.S.-China Semiconductor Summit Outcome
    May 21, 2026, 2:58 AM EDT. Shares of Teradyne, Kulicke and Soffa, Impinj, Microchip Technology, and IPG Photonics dropped sharply following the U.S.-China summit, which ended without key breakthroughs on semiconductor exports. Expectations for U.S. approval of Nvidia's H200 chip shipments to China were unmet, disappointing investors. U.S. Trade Representative Jamieson Greer indicated semiconductors were not a negotiation focus, dampening near-term optimism. Despite the sell-off, IPG Photonics' stock, known for volatility, remains down significantly from its 52-week high but has gained 34.3% year-to-date. Market reactions highlight cautious sentiment amid geopolitical tensions, with analysts skeptical about swift comprehensive deals due to national security concerns.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Salesforce stock steadies after-hours, but AI anxiety keeps CRM in focus for Monday
Previous Story

Salesforce stock steadies after-hours, but AI anxiety keeps CRM in focus for Monday

Disney stock heads into new week with Iger succession report hanging over DIS shares
Next Story

Disney stock heads into new week with Iger succession report hanging over DIS shares

Go toTop